# Eradivir

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/eradivir

- Industry: Biotechnology
- Headquarters: West Lafayette, US
- Website: www.eradivir.com
- Total disclosed funding: $0.1M
- Latest round: Seed (Apr 15, 2020)
- Investors on record: 1

## About

Based in Indiana, Eradivir, Inc. specializes in developing innovative therapies targeting infectious diseases, particularly influenza, through advanced immunotherapy technologies. Eradivir, Inc. was founded in 2020 and is headquartered in West Lafayette, Indiana, US. The company is focused on creating treatments for influenza and other diseases based on its lead molecule, EV25. The founder, Philip Low, has a notable background in biomedical research and innovation. In October 2025, Eradivir, Inc. raised USD 10 million in Series A funding. Eradivir's primary product is its lead molecule, EV25, designed to treat influenza by binding to diseased cells and enhancing immune responses. This molecule links infected cells to two anti-hapten antibodies, which helps the innate immune system to eliminate the virus effectively. The company's technology, known as Bispecific Antigenic immuno-Therapy (BAiT), aims to develop small molecule immunotherapies that may target a range of diseases, including viral infections and cancer, focusing on areas with high influenza prevalence. Eradivir generates revenue through the development and potential commercialization of its pharmaceutical products, specifically its flagship molecule, EV25. The company engages in strategic partnerships with healthcare providers, pharmaceutical distributors, and research institutions to distribute its therapies, structured around licensing deals and collaborations that enable interaction with hospitals, clinics, and research facilities essential for deploying their treatment options. The company will use the October 2025 funding to advance development of its antiviral drug candidates and support preclinical research.

## Funding rounds

- Seed, Apr 15, 2020, $0.1M — Research Bridge Partners

## Investors

- Research Bridge Partners (https://capitalatlas.ai/funds/research-bridge-partners) — Seed